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Introduction: Among elderly persons (age ≥65 years), insomnia is a prevalent sleep disorder. Lemborexant (LEM) is a dual orexin
receptor antagonist approved in multiple countries, including the United States, Japan, Canada, Hong Kong, Australia, and India, for
the treatment of insomnia in adults (age ≥18 years). Clinical trials for insomnia therapies include data from daily sleep diaries to assess
the magnitude of change quantitatively in subjective sleep outcomes, including sleep onset and maintenance. Additionally, there are
instruments that assess patient estimates of time to sleep onset and duration of nighttime awakenings. Assessment of symptom
improvement provides critical information on treatment effectiveness. The demonstration of improvement in sleep from the patient’s
perspective is important in the assessment of the effectiveness of an insomnia therapy, as insomnia is a symptom-based disorder. The
Patient Global Impression−Insomnia version (PGI-I) is a self-report instrument used to evaluate a patient’s perception (qualitative) of
the effects of their insomnia medication on their sleep relative to their sleep before starting their treatment. The PGI-I includes 3 items
related to medication effects (helped/worsened sleep; decreased/increased time to fall asleep; and increased/decreased total sleep; choices
for patient responses include: 1=positive, 2=neutral, 3=negative). The PGI-I also includes 1 item related to perceived appropriateness of
study medication strength with a different set of possible responses (choices for patient responses include: 1=too strong, 2=just right,
3=too weak). In Study E2006-G000-303 (Study 303; SUNRISE-2; NCT02952820), significantly greater percentages of subjects in the
age ≥65 years subgroup reported a positive impact of LEM versus placebo (PBO) at 1, 3 and 6 months for each of the PGI-I items
related to medication effects. The majority of subjects also reported medication strength as “just right” at 1, 3 and 6 months. PGI-I
results at 9 and 12 months for subjects age ≥65 years are presented here for subjects that received continuous treatment with LEM for up
to 12 months in Study 303.
Methods: Study 303 was a Phase 3, 12-month, double-blind, global study in adults age ≥18 years with insomnia disorder that included
a 6-month PBO-controlled period (Treatment Period 1) followed by a 6-month active-only (Treatment Period 2) period. Subjects
received PBO, LEM 5mg (LEM5) or LEM 10mg (LEM10) for the first 6 months. For Treatment Period 2, PBO-treated subjects were
rerandomized to LEM (not reported here), while LEM-treated subjects continued their original dose. Titration to higher or lower doses
was not permitted. The PGI-I was administered at Months 1, 3, 6, 9, and 12. Results for the PGI-I were analyzed by age (age ≥65 years).
Results: The Full Analysis Set comprised 949 subjects, of which 262 (27.6%;[PBO, n=89; LEM5, n=87; LEM10, n=86]) were age
≥65y. At 9 and 12 months, the majority of elderly LEM5-treated (total treated up to 9 months, n=68; total treated up to 12 months,
n=61) and LEM10-treated (total treated up to 9 months, n=61; total treated up to 12 months, n=56) subjects reported that their study
medication “helped” sleep at night (9 months: LEM5=51 [75.0%], LEM10=45 [73.8%]; 12 months: LEM5=47 [77.0%], LEM10=42
[75.0%]), reduced time to fall asleep (9 months: LEM5=59 [86.8%], LEM10=47 [77.0%]; 12 months: LEM5=53 [86.9%],
LEM10=44 [78.6%]), and increased total sleep time (9 months: LEM5=43 [63.2%], LEM10=45 [73.8%]; 12 months: LEM5=38
[62.3%], LEM10=33 [58.9%]). Also, at both 9 and 12 months, the majority of subjects in the LEM5 and LEM10 groups responded
that their medication strength was “just right” (9 months: LEM5=46 [67.6%], LEM10=37 [60.7%]; 12 months: LEM5=43 [70.5%],
LEM10=37 [66.1%]). LEM was well tolerated. Most adverse events were mild or moderate.
Conclusions: The majority of elderly subjects receiving LEM5 or LEM10 for up to 12 months reported a positive medication effect and
perceived their medication strength as “just right” at both 9 and 12 months. These results demonstrate that the similar positive perceptions
of the effects of LEM achieved during Treatment Period 1 in the elderly subgroup were sustained through Treatment Period 2.
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